How Aging Breaks the Immune System — and How We Might Fix It
A landmark 2025 review maps the molecular and cellular mechanisms driving immune aging, linking inflammaging to cancer, neurodegeneration, and infection.
Summary
Immunosenescence — the progressive decline and dysregulation of immune function with age — is driven by interconnected signaling pathway failures, accumulation of senescent cells, and shifts in immune cell populations. Key pathways including NF-κB, mTOR, JAK-STAT, and cGAS-STING become overactivated with age, while protective pathways like AMPK, melatonin, and sirtuins are suppressed. Together, these changes fuel chronic low-grade inflammation (inflammaging), reduce vaccine efficacy, impair pathogen clearance, and raise risks of cancer, neurodegenerative disease, cardiovascular disease, and autoimmunity. The review synthesizes current intervention strategies — from rapamycin analogs and senolytics to lifestyle and nutritional approaches — and highlights clinical trials already underway.
Detailed Summary
**Why This Matters** The global population is aging rapidly, and immune dysfunction in older adults is a root driver of multiple life-limiting diseases. Immunosenescence — first described by Roy Walford in the 1960s — is no longer viewed simply as immune decline but as active, harmful immune remodeling. Understanding its mechanisms is now recognized as essential for extending healthy lifespan and improving outcomes in age-related disease.
**What Was Reviewed** This comprehensive 2025 review from researchers at Sichuan University and Huazhong University of Science and Technology synthesizes molecular, cellular, and clinical evidence on immunosenescence. It covers seven core dysregulated signaling pathways, changes across innate and adaptive immune cell populations, contributions to specific age-related diseases, and a broad landscape of therapeutic interventions — including those in clinical trials.
**Key Mechanistic Findings** Four signaling pathways are pathologically upregulated in aged immune cells: NF-κB (driving inflammaging, suppressing autophagy, and protecting dysfunctional cells from apoptosis); mTOR — particularly mTORC1 (blocking autophagic clearance) and mTORC2 (impairing TCR responsiveness in CD4+ T cells); JAK-STAT (promoting SASP, skewing toward Th17 over regulatory T cells, and disrupting hematopoietic stem cell differentiation toward myeloid lineages); and cGAS-STING (sensing cytosolic damaged DNA and triggering inflammatory cytokine cascades while paradoxically impairing type I interferon production). Conversely, AMPK, melatonin signaling, and sirtuins — all of which promote autophagy, mitochondrial health, NAD+ homeostasis, and anti-inflammatory tone — decline with age. These opposing shifts reinforce each other, creating a self-amplifying inflammatory cycle.
**Cellular and Disease Consequences** At the cellular level, thymic involution shrinks naïve T cell output, the TCR repertoire contracts, and memory T cells accumulate — reducing immune flexibility. NK cells, macrophages, dendritic cells, and B cells each exhibit characteristic functional impairments. These changes contribute directly to poorer outcomes across neurodegenerative diseases (where microglia dysfunction accelerates pathology), cancers (where immunosurveillance fails and immunotherapy efficacy is reduced), infectious diseases (including COVID-19 and influenza, where vaccine responses are blunted), and autoimmune and cardiovascular diseases.
**Therapeutic Landscape** Intervention strategies include: thymic rejuvenation (IL-7, growth hormone protocols); senolytics and senomorphics (dasatinib + quercetin, navitoclax) to clear senescent immune cells; mTORC1 inhibitors (everolimus/RAD001 already showing reduced infection rates in elderly humans in Phase II trials); JAK inhibitors; melatonin supplementation; AMPK activators (metformin); NAD+ precursors (NMN, NR); and lifestyle factors including caloric restriction, exercise, and circadian rhythm optimization. Several of these have entered clinical trials with promising preliminary efficacy data.
Key Findings
- NF-κB overactivation in aged immune cells suppresses autophagy, drives inflammaging, and prevents clearance of senescent cells.
- Elevated mTORC1 signaling inhibits autophagic flux; low-dose mTORC1 inhibition with RAD001 reduced infections in elderly humans over 12 months.
- JAK-STAT hyperactivation skews immunity toward Th17 expansion, Treg suppression, and myeloid-biased hematopoiesis — hallmarks of immune aging.
- AMPK, sirtuin, and melatonin pathways decline with age, reducing mitochondrial quality, NAD+ levels, and anti-inflammatory tone.
- Senolytics, mTOR inhibitors, NAD+ precursors, and lifestyle interventions show clinical promise for reversing key features of immunosenescence.
Methodology
This is a comprehensive narrative review article synthesizing published molecular, cellular, and clinical research on immunosenescence. The authors drew on preclinical mouse models, human aging cohort data, in vitro mechanistic studies, and clinical trial results to map signaling pathway dysregulation, immune cell alterations, disease associations, and therapeutic interventions. No primary experimental data were generated by the authors.
Study Limitations
As a review article, this work is subject to publication bias in the underlying primary literature and does not provide new experimental data. Many highlighted interventions — including senolytics and NAD+ precursors — have limited large-scale RCT evidence in humans. Mechanistic findings from mouse aging models may not fully translate to human immunosenescence due to species differences in immune architecture and lifespan.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.